An Open Label Study of ANX005 in Participants With, or at Risk for, Manifest Huntington's Disease
← catalyst calendarSponsored by Annexon, Inc. (industry) · ANNX — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
28actual
Sites
6
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-25
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-09-29 | actual | When the study began enrolling |
| Primary completion | 2022-08-29 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2022-08-29 | actual | The whole study's end, after follow-up |
| First posted | 2020-08-14 | actual | When this record first appeared on the registry |
| Results posted | 2026-08-25 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-08-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Huntington Disease
Intervention
- Drug: ANX005
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)
measured From first dose of study drug up to end of study (Week 36)
Actual Dose of ANX005 Administered on Day 1
measured Day 1
Actual Dose of ANX005 Administered on Week 22
measured Week 22
Area Under the Concentration Versus Time Curve From Time 0 to t (AUC0-t) of ANX005 at Day 1
measured Pre-dose up to 4 hours post-dose on Day 1
CSF Free Complement Component 1q (C1q) at Day 1
measured Predose at Baseline (Day 1)
Blood Free C1q at Day 1
measured Predose at Baseline (Day 1)
Change From Baseline in Complement C4a in CSF at Week 24
measured Baseline, Week 24
Change From Baseline in Complement C4a in CSF at Week 36
measured Baseline, Week 36
Change From Baseline in CSF NfL Level at Week 24
measured Baseline, Week 24
Change From Baseline in CSF NfL Level at Week 36
measured Baseline, Week 36
Change From Baseline in Blood NfL Level at Week 24
measured Baseline, Week 24
Change From Baseline in Blood NfL Level at Week 36
measured Baseline, Week 36
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2020-12-16 · 3.2 MB · Prot_000.pdf
Statistical Analysis Planposted 2022-08-16 · 618 KB · SAP_001.pdf
Related
ANNX's other studiesmost recently updated first
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA) Phase 2 · Completed
- An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study) Phase 3 · Recruiting
- A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) Phase 3 · Active, not recruiting
- Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome Phase 3 · Completed
- Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS) Phase 2 · Completed
Permalink · ANNX's whole pipeline · Catalyst calendar · Every registered study · What changed